Enhancing KCC2 function or inhibiting NKCC1 has shown beneficial effects in various preclinical models of brain disorders, including epilepsy, traumatic brain injury, and AD (Capsoni et al., 2022; Hochstetler et al., 2025). Here, SLC12A2 is linked to Alzheimer disease.